Hormone replacement therapy and the risk of reproductive cancers

Journal of Psychosomatic Obstetrics and Gynaecology

Volumn 18, Issue 2, 1997, Pages 165-174

  Swan, S H ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

Breast cancer; Endometrial cancer; Epidemiology; Hormone replacement therapy; Menopause; Ovarian cancer; Risks

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

BREAST CANCER; CANCER RISK; CONFERENCE PAPER; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HUMAN; MEDICAL LITERATURE; MENOPAUSAL SYNDROME; MENOPAUSE; OVARY CANCER;

EID: 0030748274     PISSN: 0167482X     EISSN: None     Source Type: Journal    
DOI: 10.3109/01674829709085583     Document Type: Conference Paper

References (47)

1. Hammond CB. Menopause and hormone replacement therapy: An overview. Obstet Gynecol 1996;87: 2S-15S.
2. Roy JA, Sawka CA, Pritchard KI. Hormone replacement therapy in women with breast cancer: Do the risks outweigh the benefits? J Clin Oncol 1996;14:997-1006.
3. Carr BR. HRT management. The American experience. Europ J Obstet Gynecol Reprod Biol 1996;64: S17-S20.
4. Lacassagne A. Apparition de cancers de la mamelle chez la souris male, soumise a des injections de folliculine. CR Acad Sci (Paris) 1932;195:630-2.
5. Gardner WU, Smith GM, Allen E. Cancer of the mammary glands induced in male mice receiving estrogenic hormones. Arch Path 1936;21(3).
6. Suntzeff V, Burns EL, Moskop E, Loeb L. The effect of injections of estrin on the incidence of mammary cancer in various strains of mice. Am J Cancer 1936;27.
7. Shimkin MB, Grady HG. Mammary carcinoma in mice following oral administration of stilbestrol. Proc Soc Exper Biol Med 1940;45:246-8.
8. Geschickter CF. Estrogenic mammary cancer in the rat. Radiology 1939;33.
9. Perry IH. Production of carcinoma of the uterus in mice. Proc Soc Exper Biol Med 1936;35(2).
10. Allen E. Estrogenic hormones in the genesis of tumors and cancers. Endocrinol 1942;30:942-51.
11. Lupulescu A. Estrogen use and cancer incidence: A review. Cancer Invest 1995;13:287-95.
12. Lilienfeld AM. The relationship of cancer of the female breast to artificial menopause and marital status. Cancer 1956;9:927.
13. Gapstur SM, Potter JM, Sellers TA, Folsom AR. Increased risk of breast cancer with alcohol consumption in postmenopausal women. Am J Epidemiol 1992;136:1221-31.
14. Trichopolous D, MacMahon B, Cole R Menopause and breast cancer risk. J Natl Cancer Inst 1972; 48:605-13.
15. White E. Projected changes in breast cancer incidence due to the trend toward delayed childbearing. Am J Public Health 1987;77:495-7.
16. Colditz GA, Rosner BA, Speizer FE. Risk factors for breast cancer according to family history of breast cancer. J Natl Cancer Inst 1996;88:365-71.
17. Ross RK, Paganini-Hill A, Gerkins VR et al. A case-control study of menopausal estrogen therapy and breast cancer. J Am Med Assoc 1980;243:1635-9.
18. Ekbom A, Chung-cheng H, Lipworth L, Adami HO, Trichopoulos D. Intrauterine environment and breast cancer risk in women: a population based study. J Natl Cancer Inst 1997;89:71-6.
19. Michels KB, Trichopoulos D, Robins JM, et al. Birthweight as a risk factor for breast cancer. Lancet 1996;348:1542-6.
20. Henderson BE, Ross R, Bernstein L. Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1988;48:246-53.
21. Schottenfeld D. Epidemiology of endometrial neoplasia. J Cell Biochem 1995;23[S]:151-9.
22. Schneider HPG, Birkhauser M. Does HRT modify risk of gynecologic cancers. Int J Fertil 1995;40[S1]: 40-53.
23. Whittemore AS, Harris R, Itnyre J and the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk; Collaborative analysis of 12 case-control studies. II. Invasive epithelial ovarian cancers in white women. Am J Epidemiol 1992;136:1184-203.
24. Casagrande JT, Louie EW, Pike MC, et al. 'Incessant ovulation' and ovarian cancer. Lancet 1979;8135: 170-3.
25. Weiss NS. Ovary. In: Schottenfeld D, Fraumeni JF (eds). Cancer Epidemiology and Prevention. Philadelphia: Saunders 1982;871-88.
26. Henderson BE, Casagrande JT, Pike MC. The epidemiology of endometrial cancer in young women. Br J Cancer 1983;47:749-56.
27. Hulka BS, Liu ET, Lininger RA. Steroid hormones and risk of breast cancer. Cancer 1994;74:1111-24.
28. Voigt L, Weiss N, Chu J, et al. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7
29. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. J Am Med Assoc 1991; 265:1985-90.
30. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.
31. Sillera-Arenas M, Delgado-Rodriguez M, Rodrigues-Canteras R, et al. Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 1992;79:286-94.
32. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer. Results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-80.
33. Palmer JR, Rosenberg J, Clarke EA, Miller DR, Shapiro S. Breast cancer risk after Estrogen Replacement Therapy: Results from the Toronto Breast cancer Study. Am J Epidemiol 1991;134:1386-95.
34. Kaufman DW, Miller DR, Rosenberg L, et al. Noncontraceptive estrogen use and risk of breast cancer. J Am Med Assoc 1984;252:63-7.
35. Harris RE, Namboodiri KK, Wynder EL. Breast cancer risk: effects of estrogen replacement therapy and body mass. J Natl Cancer Inst 1992;84:1575-82.
36. Yang CP, Daling JR, Band PR, Gallagher RR White E, Weiss N. Noncontraceptive hormone use and risk of breast cancer. Cancer causes and Control. 1992;3: 475-9.
37. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. J Am Med Assoc 1995;274:137-42.
38. Newcomb PA, Longnecker MP, Storer BE, et al. Long term hormone replacement therapy and risk of breast cancer in post-menopausal women. Am J Epidemiol 1995;142:788-95.
39. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer. Cancer Causes Control 1994;5: 491-500.
40. Risch HA, Howe GR. Menopausal hormone usage and breast cancer in Saskatchewan; a record linkage cohort study. Am J Epidemiol 1994;139:670-83.
41. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in post-menopausal women. N Engl J Med 1995;332:1589-93.
42. Schuurman AG, van den Brandt PA, Goldbohm RA. Exogenous hormone use and the risk of post-menopausal breast cancer: results from the Netherlands cohort study. Cancer Causes Control 1995;6:416-24.
43. Colditz GA, Stampfer MJ, Willett WC, et al. Type of postmenopausal hormone use and risk of breast cancer: 12 year follow-up from the Nurses' Health Study. Cancer Causes Control 1992;3:433-9.
44. Grady D, Gebretsadik T, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85: 304-13.
45. Jick S, Walker A, Jick H. Estrogens, progesterone and endometrial cancer. Epidemiology 1993;4:20-4.
46. Brinton L, Hoover R. Estrogen replacement therapy and endometrial cancer: Unresolved issues. Obstet Gynecol 1993;29:265-71.
47. Hoover R, Gray LA Sr, Fraumeni JF Jr. Stilboestrol (diethylstilbestrol) and the risk of ovarian cancers. Lancet 1997;1:533-4.